Ph.D. in Cellular Biology, University of California
Sebastián Bernales has a degree in Biochemistry from the Universidad Católica de Chile and did his doctorate and postdoctoral studies at the University of California at San Francisco (UCSF). His first contributions to science were in the field of cellular biology, particularly learning how cells cope with the accumulation of unfolded proteins and how they control organelle homeostasis.
In 2007, he joined California-based biotechnology firm Medivation Inc., ultimately rising to the position of Vice President of Discovery Biology. Medivation, acquired by Pfizer in 2016, was a biopharmaceutical firm focused on the development and marketing of medically innovative therapies to treat serious diseases, including XTANDI (enzalutamide), an approved androgen receptor inhibitor used as a treatment for prostate cancer.
Sebastián has co-founded several biotechnology companies, including Praxis, Merken, Metagenomi, Medzyme, Mikrovia and Kreas, and has served as an advisor to others such as NotCo, Levita and Miroculus.
